Stock NAVB NAVIDEA BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Market Closed - OTC Markets
Other stock markets
 20:40:52 02/05/2024 BST 		5-day change 1st Jan Change
0.035 USD 0.00% Intraday chart for Navidea Biopharmaceuticals, Inc. -4.89% -36.59%
2023 Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding CI
2023 Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sector Update: Health Care
Top Midday Decliners
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
Navidea Biopharmaceuticals, Inc. Announces Board Changes
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.
Sector Update: Health Care Stocks Steady Late Friday
Sector Update: Health Care
Navidea Biopharmaceuticals Gets $7.5 Million Payment From Cardinal Health
Navidea Biopharmaceuticals, Inc. Announces Board Changes
Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million
Navidea Biopharmaceuticals Promotes Michael Sherman Blue to Chief Medical Officer
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Navidea Biopharmaceuticals Intends to Sell Cardinal Milestone Payment
Navidea Biopharmaceuticals, Meilleur Technologies Sign License Deal for Alzheimer's Disease Diagnosis Agent
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAVB Stock
  4. News Navidea Biopharmaceuticals, Inc.
  5. Other languages